2019 | The Medication Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label | Wang Y.-H.; Chen C.-B.; Tassaneeyakul W.; Saito Y.; Aihara M.; Choon S.E.; Lee H.Y.; Chang M.M.; Roa F.D.; Wu C.-W.; Zhang J.; Nakkam N.; Konyoung P.; Okamoto-Uchida Y.; Cheung C.M.-T.; Huang J.-W.; Ji C.; Cheng B.; Hui R.C.-Y.; CHIA-YU CHU ; Chen Y.-J.; Wu C.-Y.; Hsu C.-K.; Chiu T.-M.; Huang Y.-H.; Lu C.-W.; Yang C.-Y.; Lin Y.-T.; Chi M.-H.; Ho H.-C.; Lin J.-Y.; Yang C.-H.; Chang Y.-C.; Su S.-C.; Wang C.W.; Fan W.-L.; Hung S.-I.; Chung W.-H.; for the Asian Severe Cutaneous Adverse Reaction Consortium | Clinical Pharmacology and Therapeutics | 52 | 47 | |